Navigation Links
WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
Date:11/30/2009

SHANGHAI, Nov. 30 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company with operations in China and the United States, announced that it had been selected to the Deloitte Technology Fast 50 China 2009 list for the fifth consecutive year. The list recognizes the 50 fastest-growing companies in China's technology, media, and telecommunications industries based on revenue growth rates over the previous three years. WuXi PharmaTech is one of only two companies to have won this award for five consecutive years.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

"This recognition is a credit to the dedication and hard work of our employees and the high quality of service they deliver," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech. "Through expansion of our capabilities and capacity, both in China and the United States, we are building a broad and fully integrated platform of pharmaceutical R&D services for our customers. We are confident that our continued investment in this platform will generate strong future revenue growth."

    For more information, please contact:

    WuXi PharmaTech (Cayman) Inc.

     Ronald Aldridge (for investors)
     Director of Investor Relations
     Tel:   +1-201-585-2048
     Email: ir@wuxiapptec.com

     Stephanie Liu (for the media)
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4362
     Email: pr@wuxiapptec.com

SOURCE WuXi PharmaTech (Cayman) Inc.


'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
2. WuXi PharmaTech Announces Second-Quarter 2009 Results
3. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
4. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
5. WuXi PharmaTech Receives Award from BASF
6. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
7. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
8. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
9. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
10. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
11. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) today announced that its ... $250 million of the company,s common stock. This program ... December 31, 2017. Purchases may be made in the ... transactions from time to time as determined by United ...
(Date:4/27/2017)... ... April 27, 2017 , ... Mitotech S.A, a Luxembourg ... Hereditary Optic Neuropathy (LHON) patients. LHON is a rare devastating genetic disease that leads ... eye drops in a group of 20 patients carrying 11778, 14484 and 3460 mutations ...
(Date:4/27/2017)... Linda, Ca (PRWEB) , ... April 27, 2017 ... ... hear from a practicing internist, who will review how testing for 1,25-Dihydroxyvitamin D ... that prompt ordering of 25-OH-vitamin D and 1,25 dihydroxyvitamin D. , Dr. Gregory ...
(Date:4/27/2017)... ... April 27, 2017 , ... Volunteers supported by ... researchers, engineers, and industry professionals in visiting U.S. Congressional offices in Washington, D.C., ... the world photonics industry. , This year, National Photonics Initiative (NPI) ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
Breaking Biology News(10 mins):